| Trial ID: | L6450 |
| Source ID: | NCT05306028
|
| Associated Drug: |
Metformin Or Insulin Treatment
|
| Title: |
Metformin and Insulin to Pancreatic Cancer Related Diabetes (Type 3c)
|
| Acronym: |
|
| Status: |
ACTIVE_NOT_RECRUITING
|
| Study Results: |
NO
|
| Results: |
|
| Conditions: |
Pancretic Cancer|Diabete Mellitus
|
| Interventions: |
DRUG: Metformin or insulin treatment
|
| Outcome Measures: |
Primary: Blood glucose control rate, Blood glucose control rate before and after anti-diabetic administration, 1 week | Secondary: HbA1C control rate, HbA1C control rate before and after anti-diabetic administration, 1 week | Other: Change in serum Carbohydrate Antigen 19-9 (CA19-9) From Baseline to Day 8., Change of tumor biomarkers before and after anti-diabetic administration.Patients will collect CA19-9 values on the day of enrollment and on day 8., 1 week|Overall survival，OS, OS of subjects from recruiting to the time of death from any cause, At the end of Cycle 1 (each cycle is 28 days)
|
| Sponsor/Collaborators: |
Sponsor: Fudan University
|
| Gender: |
ALL
|
| Age: |
ADULT, OLDER_ADULT
|
| Phases: |
PHASE2
|
| Enrollment: |
20
|
| Study Type: |
INTERVENTIONAL
|
| Study Designs: |
Allocation: NA|Intervention Model: SINGLE_GROUP|Masking: NONE|Primary Purpose: TREATMENT
|
| Start Date: |
2022-08-01
|
| Completion Date: |
2025-12-31
|
| Results First Posted: |
|
| Last Update Posted: |
2025-02-21
|
| Locations: |
Department of Pancreatic Surgery, Fudan University Shanghai Cancer Center; Pancreatic Cancer Institute, Fudan University, Shanghai, Shanghai, 200032, China
|
| URL: |
https://clinicaltrials.gov/show/NCT05306028
|
